Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplatin is superior to cisplatin+vindesine and that CPT-11 monotherapy is not inferior to cisplat...

Descripción completa

Detalles Bibliográficos
Autores principales: Negoro, S, Masuda, N, Takada, Y, Sugiura, T, Kudoh, S, Katakami, N, Ariyoshi, Y, Ohashi, Y, Niitani, H, Fukuoka, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747545/
https://www.ncbi.nlm.nih.gov/pubmed/12569373
http://dx.doi.org/10.1038/sj.bjc.6600725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747545/
https://www.ncbi.nlm.nih.gov/pubmed/12569373
http://dx.doi.org/10.1038/sj.bjc.6600725

Ejemplares similares